| 25 Janvier 2021
Paris January 20, 2021: 2021: Pherecydes-Pharma, BMSystems' first therapeutic start-up, announced its intention to List on the Euronext Growth® Market in Paris
2021 will be a great year for BMSystems. We are proud that Pherecydes-Pharma, our first therapeutic start-up, announced its intention to List on the Euronext Growth® Market in Paris. "Pour les investisseurs francophones, nous vous invitons à participer le 21 janvier 2021 à 10hÂÂ à la webconférence investisseurs organisée par Pherecydes-Pharma". For all details and legal information please visit Pherecydes-Pharma new website or directly Pherecydes-Pharma IPO projet website*. With a world's first in neurodegenerative diseases, 1 therapeutic start-up, 1 exclusive out-license, and the launch of Telesphore-Pharma, BMSystems' 2nd therapeutic start-up in 2021, this announcement confirms the excellence of BMSystemsÂÂ in delivering value to patients and shareholders. Created in 2004, profitable since 2006, thanks to our recurrent clients, BMSystems addresses two complementary business targets:
We warmly invite you to visit our new website to discover our achievements in diagnostics, therapeutics, cosmetics, digital-Health and bio-processes.
Do not hesitate to contact us for more information or any business request.
Best regards, Manuel GEA About Bio-Modeling Systems Bio-Modeling Systems is the world’s first Mechanisms-Based medicine companyÂÂ that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™ models. Bio-Modeling Systems is a 100% biology driven company focused on discovery, and critical high impact decisions making and address the following Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health with its dual business model: Contractual or Collaborative R&D programs. For all details and presentations, visit our new website.
CEO Bio-Modeling Systems
* The following information does not constitute or should not be considered as a public offering, an offer to subscribe or a public solicitation in preparation for a public offering of Pherecydes Pharma’s securities.
